ClinicalTrials.gg
CompletedNCT01682135Updated Aug 26, 2016Results posted

A Study in Participants With Advanced Solid Tumors

A Phase 1 interventional study of Ramucirumab in Solid Tumor, sponsored by Eli Lilly and Company. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This trial is testing ramucirumab (LY3009806) administered to Chinese participants with advanced solid tumors that are resistant to standard therapy or for whom no standard therapy is available. The purpose of this study is to evaluate how safe ramucirumab is and whether it causes any side effects. The study will also measure how much ramucirumab gets into the blood stream and how long it takes the body to get rid of it.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese participants with histopathologically or diagnosed advanced solid tumor
  • Did not respond to standard therapy or no standard therapy is available
  • Measurable or nonmeasurable disease according to the (RECIST)
  • (ECOG) performance status score of 0-1 at study entry
  • Able to provide written
  • A of >3 months
  • Adequate hematologic function, as defined by: (ANC) ≥1500 per cubic millimeter (mm\^3); concentration ≥9 grams per deciliter (g/dL); and count ≥100,000/mm\^3
  • Adequate hepatic function, as defined by: Total level ≤1.5 x the (ULN) (in participants with known Gilbert Syndrome, a total bilirubin ≤ 3.0 x ULN with direct bilirubin ≤ 1.5 x ULN); (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN (or ≤5 x ULN if the participant has liver
  • Adequate renal function, as defined by: Serum creatinine level ≤1.5 x ULN; or calculated serum (Cockcroft-Gault) ≥50 milliliters per minute (mL/min)
  • Urinary protein is 0 or 1+ on dipstick but no edema nor serum albumin \< lower level of normal
  • Adequate coagulation function, as defined by: (INR) ≤1.5, or prothrombin time (PT) ≤1.5 x ULN and activated partial thromboplastin time (aPTT) ≤1.5 x ULN (unless receiving anticoagulation therapy)
  • Agrees to use adequate during the study period and for 12 weeks after the last dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Had chemotherapy or therapeutic radiotherapy within 14 days (6 weeks for nitrosoureas or mitomycin C) before entering the study or the participant has ongoing side effects (≥ Grade 2) due to previously administered agents
  • Has obvious evidence of intratumor cavitation
  • Has undergone major surgery within 28 days before study entry or has had a central venous access device inserted within 7 days before study entry
  • Has a history of gastrointestinal perforation, postoperative bleeding complications, or wound complications from a surgical procedure
  • Has elective or planned surgery to be conducted during the trial
  • Has documented and/or symptomatic brain or
  • Has uncontrolled ongoing illness, for example: thrombotic or hemorrhagic disorders; hemoptysis; ongoing infection requiring systemic antibiotic treatment; congestive heart failure, angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months; stroke, (TIA), or other grade 3-4 arterial thromboembolic event occurring within 6 months; uncontrolled hypertension (≥150/≥90 millimeters of mercury [mmHg]); cardiac arrhythmia that requires treatment or asymptomatic sustained ventricular tachycardia; peripheral neuropathy ≥Grade 2; (HIV) or active, uncontrolled hepatitis, liver cirrhosis at a level of Class B (or worse), liver cirrhosis (any degree) and a history of hepatic encephalopathy or ascites resulting from cirrhosis. (Clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis)
  • Has a serious or nonhealing wound, ulcer, or bone fracture within 28 days before study entry
  • Has experienced any Grade 3 or 4 gastrointestinal bleeding within 3 months before study entry
  • Has a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess \<6 months before randomization, or the participant has a history of poorly controlled or recurrent inflammatory bowel disease (including Crohn's disease or ulcerative colitis)
  • Has participated in a clinical study of a non-approved experimental agent or procedure within 4 weeks prior to study entry for small molecules, or 8 weeks before study entry for non-approved monoclonal antibodies
  • Has a known allergy to ramucirumab or its , a monoclonal antibody (MAb), or any other therapeutic protein, such as fresh frozen plasma, human serum albumin (HSA), cytokines, or interleukins. If there is suspicion that the participant may have an allergy, the participant should be excluded
  • Is pregnant (confirmed by urine or serum pregnancy test) or lactating
  • Has known alcohol or drug dependency
  • Is receiving chronic therapy with nonsteroidal anti-inflammatory agents (NSAIDs)
  • Is not considered to be suitable for this study, in the opinion of the investigator
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Ramucirumab

    Ramucirumab administered intravenously (IV) at escalating doses (6 milligrams per kilogram \[mg/kg\] up to 10 mg/kg) every 2-3 weeks for 6 weeks (1 Cycle). Treatment may continue until discontinuation criterion is met.

    Biological: Ramucirumab

Interventions

  • BiologicalRamucirumab

    Administered IV.

    Also known as: IMC-1121B, LY3009806

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs)

    A summary of AEs and SAEs considered by the investigator to be drug-related is located in the Reported Adverse Events module. An AE is summarized if the onset date is on or after the first dose of study drug and within 30 days after the last dose, or it occurred before the first dose of study drug and worsened while on the therapy.

    Time frame: Baseline through Study Completion (Up to 12 Weeks)

  2. Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab

    Time frame: Cycle 1 & 2: Predose, End of Infusion, 0.5 hour (h) ,1h, 2h, 4h, 8h, 24h, 48h,72h or 96h, 168h, 264h, and 336h Postdose (and 504h Postdose Cohort 2 only)

  3. Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab

    Time frame: Cycle 2-5: Predose

  4. Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab

    Cycle 1 analysis performed: Area Under the Concentration-Time Curve Zero to Infinity (AUC\[0-∞\]); Cycle 2 analysis performed: Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State (AUC\[τ,ss\])

    Time frame: Cycle 1 & 2: Predose, End of Infusion, 0.5 hour (h) ,1h, 2h, 4h, 8h, 24h, 48h,72h or 96h, 168h, 264h, and 336h Postdose (and 504h Postdose Cohort 2 only)

Secondary outcomes

  1. Duration of Response

    Participants achieved an objective response if they had a best overall response of complete response (CR) or partial response (PR). According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. For each participant who is not known to have died or to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, duration of tumor response was to be censored at the date of the participant's last objective tumor assessment prior to that cut-off date.

    Time frame: Time Between Meeting Response Criteria and Progressive Disease or Death Due to Any Cause (Up to 10 Weeks)

  2. Duration of Stable Disease (SD)

    Duration of SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. SD is measured at the start of the study drug until progressive disease or death due to any cause, whichever is first. Censoring occurred if a participant did not have a complete baseline disease assessment, initiated on another anti-cancer therapy (censored at the date of the last complete objective progression-free disease assessment before initiation of the new therapy), was not known to have died or had objective progression as of the data inclusion cutoff date for analysis.

    Time frame: Baseline to Progressive Disease or Death Due to Any Cause (Up to 10 Weeks)

  3. Time to Disease Progression

    Time to progressive disease was measured from the start of study drug until progressive disease. Censoring occurred if a participant did not have a complete baseline disease assessment, initiated on another anti-cancer therapy (censored at the date of the last complete objective progression-free disease assessment before initiation of the new therapy), was not known to have died or had objective progression as of the data inclusion cutoff date for analysis.

    Time frame: Baseline to Progressive Disease (Up to 10 Weeks)

  4. Number of Participants With Anti-Ramucirumab Antibodies

    A sample will be considered positive for circulating anti-ramucirumab antibodies if it exhibits a post-baseline antibody level that exceeds the upper 95% confidence interval of the mean determined from the normal anti-ramucirumab level seen in healthy untreated individuals. A participant will be considered to have an anti-ramucirumab response if there are 2 consecutive positive samples or if the final sample tested is positive.

    Time frame: Cycle 1: Pre-infusion, Cycle 2: Pre-infusion, Cycle 3: Pre-infusion

  5. Number of Participants With Best Objective Response (BOR)

    Participants achieved disease control if they had a BOR of CR, PR or SD. Progressive Disease (PD) and those participants which were Not Evaluable (NE) were also reported. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started.

    Time frame: Baseline to Progressive Disease or Participant Stopped Study (Up to 10 Weeks)

07

Results

Posted Aug 26, 2016

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 - 6 mg/kg/2w RamucirumabCohort 2 - 10 mg/kg/3w RamucirumabCohort 3 - 8 mg/kg/2w Ramucirumab
Started61012
Received at least 1 dose of study drug61012
Completed61012
Not completed000

Outcome measures

PrimaryNumber of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs)

A summary of AEs and SAEs considered by the investigator to be drug-related is located in the Reported Adverse Events module. An AE is summarized if the onset date is on or after the first dose of study drug and within 30 days after the last dose, or it occurred before the first dose of study drug and worsened while on the therapy.

Time frame:
Baseline through Study Completion (Up to 12 Weeks)
Reported as:
Number · Participants
Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs)
ParticipantsCohort 1: 6 mg/kg/2w RamucirumabCohort 2: 10 mg/kg/3w RamucirumabCohort 3: 8 mg/kg/2w Ramucirumab
Drug-Related Adverse Event4810
Serious Adverse Event010
PrimaryPharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab
Time frame:
Cycle 1 & 2: Predose, End of Infusion, 0.5 hour (h) ,1h, 2h, 4h, 8h, 24h, 48h,72h or 96h, 168h, 264h, and 336h Postdose (and 504h Postdose Cohort 2 only)
Reported as:
Geometric mean · microgram/milliliter (µg/mL)
Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab
microgram/milliliter (µg/mL)Cohort 1: 6 mg/kg/2w RamucirumabCohort 2: 10 mg/kg/3w RamucirumabCohort 3: 8 mg/kg/2w Ramucirumab
Cycle 1 (n = 6, 9, 12)155 ± 13186 ± 22190 ± 39
Cycle 2 (n = 1, 6, 8)NA ± NA219 ± 22239 ± 19
PrimaryPharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab
Time frame:
Cycle 2-5: Predose
Reported as:
Geometric mean · µg/mL
Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab
µg/mLCohort 1: 6 mg/kg/2w RamucirumabCohort 2: 10 mg/kg/3w RamucirumabCohort 3: 8 mg/kg/2w Ramucirumab
Cycle 2 (n = 5, 8, 10)36.9 ± 3529.5 ± 9059.7 ± 26
Cycle 3 (n = 1, 2, 5)NA ± NANA ± NA68.7 ± 28
Cycle 4 (n = 1, 2, 4)NA ± NANA ± NA79.6 ± 26
Cycle 5 (n = 0, 3, 4)NA ± NA56.5 ± 1792.5 ± 19
PrimaryPharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab

Cycle 1 analysis performed: Area Under the Concentration-Time Curve Zero to Infinity (AUC\[0-∞\]); Cycle 2 analysis performed: Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State (AUC\[τ,ss\])

Time frame:
Cycle 1 & 2: Predose, End of Infusion, 0.5 hour (h) ,1h, 2h, 4h, 8h, 24h, 48h,72h or 96h, 168h, 264h, and 336h Postdose (and 504h Postdose Cohort 2 only)
Reported as:
Geometric mean · Microgram*day/milliliter (µg*day/mL)
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab
Microgram*day/milliliter (µg*day/mL)Cohort 1: 6 mg/kg/2w RamucirumabCohort 2: 10 mg/kg/3w RamucirumabCohort 3: 8 mg/kg/2w Ramucirumab
Cycle 1 AUC(0-∞) (n = 5, 7, 7)870 ± 141430 ± 311350 ± 9
Cycle 2 AUC(τ,ss) (n = 1, 6, 8)NA ± NA1630 ± 321540 ± 16
SecondaryDuration of Response

Participants achieved an objective response if they had a best overall response of complete response (CR) or partial response (PR). According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. For each participant who is not known to have died or to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, duration of tumor response was to be censored at the date of the participant's last objective tumor assessment prior to that cut-off date.

Time frame:
Time Between Meeting Response Criteria and Progressive Disease or Death Due to Any Cause (Up to 10 Weeks)
Reported as:
Median · Months
Duration of Response
MonthsCohort 1: 6 mg/kg/2w RamucirumabCohort 2: 10 mg/kg/3w RamucirumabCohort 3: 8 mg/kg/2w Ramucirumab
Duration of Response0 (0 to 0)0 (0 to 0)0 (0 to 0)
SecondaryDuration of Stable Disease (SD)

Duration of SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. SD is measured at the start of the study drug until progressive disease or death due to any cause, whichever is first. Censoring occurred if a participant did not have a complete baseline disease assessment, initiated on another anti-cancer therapy (censored at the date of the last complete objective progression-free disease assessment before initiation of the new therapy), was not known to have died or had objective progression as of the data inclusion cutoff date for analysis.

Time frame:
Baseline to Progressive Disease or Death Due to Any Cause (Up to 10 Weeks)
Reported as:
Median · Months
Duration of Stable Disease (SD)
MonthsCohort 1: 6 mg/kg/2w RamucirumabCohort 2: 10 mg/kg/3w RamucirumabCohort 3: 8 mg/kg/2w Ramucirumab
Duration of Stable Disease (SD)NA (NA to NA)5.68 (2.79 to 12.22)5.29 (2.92 to 6.87)
SecondaryTime to Disease Progression

Time to progressive disease was measured from the start of study drug until progressive disease. Censoring occurred if a participant did not have a complete baseline disease assessment, initiated on another anti-cancer therapy (censored at the date of the last complete objective progression-free disease assessment before initiation of the new therapy), was not known to have died or had objective progression as of the data inclusion cutoff date for analysis.

Time frame:
Baseline to Progressive Disease (Up to 10 Weeks)
Reported as:
Median · Months
Time to Disease Progression
MonthsCohort 1: 6 mg/kg/2w RamucirumabCohort 2: 10 mg/kg/3w RamucirumabCohort 3: 8 mg/kg/2w Ramucirumab
Time to Disease Progression1.41 (1.35 to NA)3.38 (1.28 to 8.21)3.94 (1.22 to 5.55)
SecondaryNumber of Participants With Anti-Ramucirumab Antibodies

A sample will be considered positive for circulating anti-ramucirumab antibodies if it exhibits a post-baseline antibody level that exceeds the upper 95% confidence interval of the mean determined from the normal anti-ramucirumab level seen in healthy untreated individuals. A participant will be considered to have an anti-ramucirumab response if there are 2 consecutive positive samples or if the final sample tested is positive.

Time frame:
Cycle 1: Pre-infusion, Cycle 2: Pre-infusion, Cycle 3: Pre-infusion
Reported as:
Number · Participants
Number of Participants With Anti-Ramucirumab Antibodies
ParticipantsCohort 1: 6 mg/kg/2w RamucirumabCohort 2: 10 mg/kg/3w RamucirumabCohort 3: 8 mg/kg/2w Ramucirumab
Number of Participants With Anti-Ramucirumab Antibodies000
SecondaryNumber of Participants With Best Objective Response (BOR)

Participants achieved disease control if they had a BOR of CR, PR or SD. Progressive Disease (PD) and those participants which were Not Evaluable (NE) were also reported. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started.

Time frame:
Baseline to Progressive Disease or Participant Stopped Study (Up to 10 Weeks)
Reported as:
Number · Participants
Number of Participants With Best Objective Response (BOR)
ParticipantsCohort 1: 6 mg/kg/2w RamucirumabCohort 2: 10 mg/kg/3w RamucirumabCohort 3: 8 mg/kg/2w Ramucirumab
Complete Response (CR)000
Partial Response (PR)000
Stable Disease (SD)378
Progressive Disease (PD)333
Not Evaluable (NE)001

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 - 6mg/kg/2w Ramucirumab—1/6 (16.7%)6/6 (100%)
Cohort 2 - 10mg/kg/3w Ramucirumab—2/10 (20%)10/10 (100%)
Cohort 3 - 8mg/kg/2w Ramucirumab—1/12 (8.3%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1 - 6mg/kg/2w RamucirumabCohort 2 - 10mg/kg/3w RamucirumabCohort 3 - 8mg/kg/2w Ramucirumab
FatigueGeneral disorders1/60/100/12
Upper gastrointestinal haemorrhageGastrointestinal disorders0/61/100/12
Blood bilirubin increasedInvestigations0/61/100/12
Impaired gastric emptyingGastrointestinal disorders0/60/101/12
Most frequent other events
Showing 10 of 102
Most frequent other events
EventCohort 1 - 6mg/kg/2w RamucirumabCohort 2 - 10mg/kg/3w RamucirumabCohort 3 - 8mg/kg/2w Ramucirumab
FatigueGeneral disorders6/68/105/12
HypertensionVascular disorders3/67/105/12
Aspartate aminotransferase increasedInvestigations2/65/107/12
ConstipationGastrointestinal disorders3/61/101/12
Alanine aminotransferase increasedInvestigations2/65/105/12
Decreased appetiteMetabolism and nutrition disorders2/65/103/12
DizzinessNervous system disorders3/61/103/12
ProteinuriaRenal and urinary disorders3/63/106/12
DyspnoeaRespiratory, thoracic and mediastinal disorders3/62/100/12
EpistaxisRespiratory, thoracic and mediastinal disorders3/63/101/12

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Cohort 1 - 6 mg/kg/2w RamucirumabCohort 2 - 10 mg/kg/3w RamucirumabCohort 3 - 8 mg/kg/2w RamucirumabTotal
Mean51.20 ± 9.06052.92 ± 9.50958.18 ± 9.44454.80 ± 9.536
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 - 6 mg/kg/2w RamucirumabCohort 2 - 10 mg/kg/3w RamucirumabCohort 3 - 8 mg/kg/2w RamucirumabTotal
Female43714
Male27514
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 - 6 mg/kg/2w RamucirumabCohort 2 - 10 mg/kg/3w RamucirumabCohort 3 - 8 mg/kg/2w RamucirumabTotal
American Indian or Alaska Native0000
Asian6101228
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1 - 6 mg/kg/2w RamucirumabCohort 2 - 10 mg/kg/3w RamucirumabCohort 3 - 8 mg/kg/2w RamucirumabTotal
China6101228
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200032, China
09

References and documents

Publications

  • Cao J, Ji D, Chen Z, Shen W, Wang J, Li B, Chi H, Long A, Gao L, Li J. Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors. Oncologist. 2017 Jun;22(6):638-e56. doi: 10.1634/theoncologist.2017-0137. Epub 2017 May 2. PubMed 28465370 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2012
First posted
Sep 10, 2012
Start
Nov 2012
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Aug 26, 2016
Last update
Aug 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01682135
Responsible party
Sponsor
First posted
Sep 10, 2012
Start date
Nov 2012
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Aug 26, 2016
Last update
Aug 26, 2016

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion